Platelet aggregation blocker shows promise as acute stroke therapy

NEW YORK (Reuters Health) – Following acute stroke, treatment with tirofiban effectively limits the amount of ischemic brain tissue that undergoes infarction, according to a report published in the February 12th issue of Neurology.

Tirofiban, a nonpeptide glycoprotein IIb/IIIa receptor antagonist, is produced by Merck and Co., Inc., Whitehouse Station, New Jersey, under the tradename Aggrastat.

Dr. M. Siebler and colleagues, from the University Dusseldorf in Germany, compared the infarct-related outcomes of 10 acute stroke patients treated with tirofiban and heparin with those of 10 matched patients treated with heparin only. Tirofiban was started within a median of 9 hours after symptom onset and continued for at least 24 hours. MRI was used to determine the amount of ischemic/infarcted tissue at baseline and 1 week later.

Treatment with tirofiban salvaged significantly more ischemic tissue than did solitary heparin therapy (p = 0.029), the authors note. No significant hemorrhagic events occurred in any patient and both groups had similar clinical scores at 1-week followup.

The current findings suggest that glycoprotein IIb/IIIa receptor antagonists such as tirofiban may play a role in acute stroke therapy, the researchers note. Further clinical trials using clinical outcome parameters are warranted.

0 תגובות

השאירו תגובה

רוצה להצטרף לדיון?
תרגישו חופשי לתרום!

כתיבת תגובה

מידע נוסף לעיונך

כתבות בנושאים דומים